Copyright
©The Author(s) 2021.
World J Gastrointest Endosc. Jan 16, 2021; 13(1): 1-12
Published online Jan 16, 2021. doi: 10.4253/wjge.v13.i1.1
Published online Jan 16, 2021. doi: 10.4253/wjge.v13.i1.1
Systemic gastrointestinal amyloidosis | Localized gastrointestinal amyloidosis |
More common subtype | Less common subtype |
Amyloid production at a remote location with subsequent deposition in the GI tract | Amyloid production in the GI tract with subsequent deposition locally |
Presence of amyloid precursor proteins in the blood | Amyloid precursor proteins absent in the blood |
Associated with plasma cell dyscrasia, chronic inflammatory conditions, dialysis, or hereditary conditions | Not associated with an underlying disease pathology |
Amyloid precursor protein deposited include AL, AA, Aβ2M and ATTR | Amyloid precursor protein most deposited is AL |
Management consists of symptomatic management and treatment of the underlying etiology | Management consists of observation or surgical excision of the localised deposition |
Prognosis depends on the type and amount of amyloid deposition | Good prognosis. No transition to systemic type |
- Citation: Dahiya DS, Kichloo A, Singh J, Albosta M, Wani F. Gastrointestinal amyloidosis: A focused review. World J Gastrointest Endosc 2021; 13(1): 1-12
- URL: https://www.wjgnet.com/1948-5190/full/v13/i1/1.htm
- DOI: https://dx.doi.org/10.4253/wjge.v13.i1.1